Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS G13R |
| Therapy | Tipifarnib + Trametinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS G13R | Advanced Solid Tumor | sensitive | Tipifarnib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment with Zarnestra (tipifarnib) and Mekinist (trametinib) decreased viability of HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R compared to Zarnestra (tipifarnib) treatment alone in culture (PMID: 39152269). | 39152269 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39152269) | Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors. | Full reference... |